Page 83 - 2021_04-Haematologica-web

A new promising CAR.CD30 T-cell therapy for CD30+ lymphoma.
References
1. Sadelain M. Chimeric antigen receptors: driving immunology towards synthetic biol- ogy. Curr Opin Immunol. 2016;41:68-76.
2. Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refracto- ry B-cell lymphomas. N Engl J Med. 2017;377(26):2545-2554.
3. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabta- gene ciloleucel in refractory large B-cell lym- phoma (ZUMA-1): a single-arm, multicen- tre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31-42.
4.Rezvani AR, Storer B, Maris M, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(2):211- 217.
5. von Tresckow B, Moskowitz CH. Treatment of relapsed and refractory Hodgkin lymphoma. Semin Hematol. 2016;53(3):180-185.
6. Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B- cell lymphoma. Blood. 2011;118(10):2659- 2669.
7. Sabattini E, Pizzi M, Tabanelli V, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;98(8):e81-82.
8.Bossard C, Dobay MP, Parrens M, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014;124(19):2983-2986.
9. Berger GK, Gee K, Votruba C, McBride A, Anwer F. Potential application and preva- lence of the CD30 (Ki-1) antigen among solid tumors: a focus review of the literature. Crit Rev Oncol Hematol. 2017;113:8-17.
10. Pallesen G, Hamilton-Dutoit SJ. Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma. Am J Pathol. 1988;133(3):446-450.
11. Hittmair A, Rogatsch H, Hobisch A, Mikuz G, Feichtinger H. CD30 expression in semi- noma. Hum Pathol. 1996;27(11):1166-1171.
12. de Bruin PC, Gruss HJ, van der Valk P, Willemze R, Meijer CJ. CD30 expression in normal and neoplastic lymphoid tissue: bio- logical aspects and clinical implications. Leukemia. 1995;9(10):1620-1627.
13. Agrawal B, Reddish M, Longenecker BM. CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors. J Immunol. 1996;157(8):3229-3234.
14. Bonthapally V, Wu E, Macalalad A, et al. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous trans- plant: meta-analysis versus historical data. Curr Med Res Opin. 2015;31(5):993-1001.
15. Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentux- imab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562-1566.
16.Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients
with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709-2717.
17. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell trans- plantation in patients with Hodgkin's lym- phoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853-1862.
18. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008;60(12):1421-1434.
19. Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr virus specific cytotoxic T lym- phocytes expressing the anti-CD30zeta arti- ficial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007;110(7):2620-2630.
20. Di Stasi A, De Angelis B, Rooney CM, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activ- ity in a Hodgkin tumor model. Blood. 2009;113(25):6392-6402.
21. Wang CM, Wu ZQ, Wang Y, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open- label phase I trial. Clin Cancer Res. 2017;23(5):1156-1166.
22. Ramos CA, Ballard B, Zhang H, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor- redirected lymphocytes. J Clin Invest. 2017;127(9):3462-3471.
23. Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118(23):6050-6056.
24. Heczey A, Louis CU, Savoldo B, et al. CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol Ther. 2017;25(9):2214-2224.
25. Wahl AF, Klussman K, Thompson JD, et al. The anti-CD30 monoclonal antibody SGN- 30 promotes growth arrest and DNA frag- mentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002;62(13):3736-3742.
26.Quintarelli C, Orlando D, Boffa I, et al. Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology. 2018;7 (6):e1433518.
27. Di Stasi A, De Angelis B, Savoldo B. Gene therapy to improve migration of T cells to the tumor site. Methods Mol Biol. 2010;651:103-118.
28. Zheng Z, Chinnasamy N, Morgan RA. Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expres- sion by flow cytometry. J Transl Med. 2012;10:29.
29. Zhu Y, Tan Y, Ou R, et al. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review
of efficacy and safety in clinical trials. Eur J
Haematol. 2016;96(4):389-396.
30.Turtle CJ, Hanafi LA, Berger C, et al.
31.
32.
33.
Immunotherapy of non-Hodgkin's lym- phoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116.
Hombach AA, Rappl G, Abken H. Blocking CD30 on T cells by a dual specific CAR for CD30 and colon cancer antigens improves the CAR T cell response against CD30(-) tumors. Mol Ther. 2019;27(10):1825-1835. Weinkove R, George P, Dasyam N, McLellan AD. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin Transl Immunol. 2019;8(5):e1049.
Hombach AA, Rappl G, Abken H. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms com- bined CD28-OX40 "super-stimulation". Mol Ther. 2013;21(12):2268-2277.
34. Hombach AA, Chmielewski M, Rappl G, Abken H. Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation. Hum Gene Ther. 2013;24(3):259-269.
35. Cheng Z, Wei R, Ma Q, et al. In vivo expan- sion and antitumor activity of coinfused CD28- and 4-1BB-engineered CAR-T cells in patients with B cell leukemia. Mol Ther. 2018;26(4):976-985.
36. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and per- sistence of chimeric antigen receptor-modi- fied T cells in lymphoma patients. J Clin Invest. 2011;121(5):1822-1826.
37. Ramos CA, Rouce R, Robertson CS, et al. In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin's lymphomas. Mol Ther. 2018;26(12):2727-2737.
38. Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of pri- mary human T cells. Mol Ther 2005;12(5):933-941.
39. Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimu- lation by a chimeric antigen receptor abro- gates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology. 2012;1(4):458-466.
40. Orlando D, Miele E, De Angelis B, et al. Adoptive immunotherapy using PRAME- specific T cells in medulloblastoma. Cancer Res. 2018;78(12):3337-3349.
41. Wein F, Kuppers R. The role of T cells in the microenvironment of Hodgkin lymphoma. JJ Leukoc Biol. 2016;99(1):45-50.
42.Wein F, Weniger MA, Hoing B, et al. Complex immune evasion strategies in clas- sical Hodgkin lymphoma. Cancer Immunol Res. 2017;5(12):1122-1132.
43.Gargett T, Brown MP. The inducible cas- pase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxici- ties of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235.
haematologica | 2021; 106(4)
999